Entecavir: A new treatment option for chronic hepatitis B

INSERM Unit 271, Liver Department, Hôtel Dieu Hospital, Hospices Civils de Lyon, Université Lyon 1, 151 Cours Albert Thomas, 69003 Lyon, France.
Journal of Clinical Virology (Impact Factor: 3.02). 06/2006; 36(1):8-12. DOI: 10.1016/j.jcv.2006.01.010
Source: PubMed


Because of the slow kinetics of viral clearance and the spontaneous genetic variability of hepatitis B virus (HBV), antiviral therapy of chronic hepatitis B remains a clinical challenge. Despite the recent development of lamivudine, adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic HBV infection, there is still a major need for new antiviral compounds. Entecavir, a guanosine analog, has been recently approved in US for the therapy of chronic hepatitis B and its registration is expected soon in Europe. Extensive studies have been performed to characterize its antiviral activity in enzymatic and tissue culture models, as well as in animal models of HBV infection. In clinical trails, entecavir administration was associated with a significantly more potent viral suppression compared to lamivudine, and a significant advantage in terms of biochemical and histological improvement compared to lamivudine. Entecavir was tolerated as well as lamivudine in these phase III trials. No case of resistance was detected after two years of therapy in nucleoside naive patients. Treatment of patients with lamivudine failure requires a higher dosage of entecavir and induces a significant decline in viraemia levels. However, 10% of these patients developed entecavir resistance after two years of therapy. The availability of entecavir as a new treatment option is providing clinicians more choice to keep both viral replication and liver disease under control. This provides new hope for improved treatment concepts for chronic HBV infection.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been shown that cellular immunity, especially by cytotoxic T lymphocytes (CTLs), NK cells and NK-T cells, plays a central role in the control of virus infection. In addition, CD4+ T cells facilitate both CTL and B-cell responses. Hyporesponsiveness of HBV-specific T cells in peripheral blood has been shown in patients with chronic HBV infection. Interferon and nucleos(t)ide analogs, such as lamivudine, adefovir, entecavir and tenofovir, are the currently available treatments. Unfortunately, the efficacy of nucleos(t)ide analogs is limited by viral reactivation by the emergence of escaped mutants in cases of prolonged treatment. Therefore, immunotherapy is one of the significant options to eradicate or control HBV replication without drugs. The aim of immunotherapies is to decrease the levels of viral replication and to eradicate infected hepatocytes. For this reason, new strategies for immunotherapies by vaccination target not only the induction or stimulation of CD4+ and CD8+ T cell responses, but also the induction of proinflammatory cytokines capable of controlling viral replication. We will review the immunopathogenesis of persistent HBV infection, especially focusing on the mechanisms of immune suppression. Then we will review the immunotherapy for HBV persistent infection.
    No preview · Article · Apr 2009 · Clinical Journal of Gastroenterology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reacting, nonlinearly adsorbing solute transport in chemically heterogeneous oils is studied. Assuming adsorption is adequately described with the Freundlich equation, random variation of the adsorption coefficient is assumed to describe the heterogeneity. In a homogeneous case, traveling wave fronts develop, characterized by a constant velocity and a constant front shape. Using the method of moments, an analytical expression is derived to describe the constant variance of the traveling wave front. Deviations from the analytical variance and velocity, both calculated with an average adsorption coefficient, show that column scale heterogeneity has significant effects on front spreading and front movement. Expected values of front velocity and variance are computed as averages of values of 600 randomly generated columns. The nonlinear process causes small deviations from the case with average parameters. The ensemble average concentration front, representing an average front for the flow domain, shows that three mechanisms are responsible for the front spreading. At early displacement times the front spreading is caused by the thickness of the individual traveling waves. Subsequently, the effect of the internal variation of the adsorption coefficient (column scale heterogeneity) increases, whereas at large displacement times the front spreading is dominated by the different retardation coefficients of the different columns. The latter effect causes the variance to increase in proportion to t2. An analytical approximation is derived for the ensemble average front, ignoring column scale heterogeneity.
    No preview · Article · Jan 1993
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a major goal of antiviral therapy to improve the clinical outcome of the patients. Antiviral treatment of chronic hepatitis B relies currently on immune modulators such as interferon alpha and its pegylated form, and viral polymerase inhibitors. Because of the slow kinetics of viral clearance and the spontaneous viral genome variability, viral mutants resistant to nucleoside analogs may be selected. However, the development of new antiviral agents is rapidly improving the offing of therapy of chronic hepatitis B. These new therapeutic advances are reviewed in this manuscript.
    Preview · Article · Oct 2006 · Antiviral Research
Show more